MyoKardia is a clinical stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.Read More
Recent Press Releases
05/02/17MyoKardia to Announce First Quarter 2017 Financial Results and Host Conference Call on Tuesday, May 9, 2017
NASDAQ GS | MYOK (Common Stock)
$14.45 + 0.50
06/23/174:01 p.m. ETData provided by Nasdaq. Minimum 15 minutes delayed.
There are currently no events scheduled.